MILLENNIUM

20001

FEB 2 6 2004

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Burgen Hour Statement: Inits form is estimated to band of thouse the Chief Information Officer, U.S. Patent and Trademark Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Washington, DC 20231.

In re application of:

Ramakrishnan, Vanitha et al.

Application No.:

09/775,803

Group No.:

1635

Filed:

February 5, 2001

Examiner:

Whiteman, Brian A.

For:

TRANSGENIC ANIMALS HAVING A MODIFIED GLYCOPROTEIN V GENE

AND METHODS FOR THEIR USE

Practitioner's Docket No. MPI98-149P1USRCEM PATENT

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, fax number 1-703-872-9306, on February 26, 2004.

Paula Swirka

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Amendment after Final and Response Transmittal (in duplicate)

4 pages

Amendment after Final and Response

9 pages

Notice of Appeal from the Primary Examiner to the Board of Patent Appeals and Interferences (37 CFR 1.191) (in duplicate)

6 pages

This Certificate of Transmission under 37 CFR 1.8

1 page

Total Pages

20 pages

(Including this cover sheet)

TO/SB/97 (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Practitioner's Docket No. MP198-149P1USRCEM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ramakrishnan, Vanitha et al.

Application No.:

09/775,803

1635 Group No.:

Filed: For:

February 5, 2001

Examiner:

Whiteman, Brian A.

TRANSGENIC ANIMALS HAVING A MODIFIED GLYCOPROTEIN V GENE

AND METHODS FOR THEIR USE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL AND RESPONSE TRANSMITTAL

Transmitted herewith for this application are: 1.

This Amendment after Final and Response Transmittal (2 pages, in duplicate); Я.

Amendment after Final and Response (9 pages); b.

- Notice of Appeal from the Primary Examiner to the Board of Patent Appeals and C. Interferences (37 C.F.R. Section 1.191) (3 pages, in duplicate); and
- Certificate of Transmission under 37 CFR 1.8 (1 page). d.

STATUS

Applicant is other than a small entity. 2.

February 26, 2004

PETITION FOR EXTENSION OF TIME

If an extension of time is required, please consider this a petition therefor.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.10* 37 C.F.R. SECTION 1.8(a) as "Express Mail Post Office to Addressee" with sufficient postage as first class mail. Mailing Label No) TRANSMISSION transmitted by facsimile to the Patent and Trademark Office (703-872-9306) \mathbf{X} Signature Paula Swirka

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI98-149P1USRCEM

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	OTHER THAN A SMALL ENTITY			
Claims Remaining After Amendment			Highest No. Previously Paid For		Present Extra	Rate		Addit. Fee
Total	15	Minus	28	=	0	\$18.00 =	=	\$0.00
Indep.	5	Minus	5		0	\$86.00	=	\$0.00
First Presentation of Multiple Dependent			0			\$290.00	=	\$0.00
Claims						Total Addit, Fee		\$0.00

Total additional fee for claims required

\$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$330.00 (Notice of Appeal fee).

A duplicate of this transmittal is attached.

FEE DEFICIENCY

- If any additional extension and/or fee is required, charge Account No. 501668.
 If any additional fee for claims is required, charge Account No. 501668.
- 7. Correspondence Address
 Direct all future correspondence to:

Customer Number 30405 OR

Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street

Cambridge, MA 02139

February 26, 2004

MILLENNIUM PHARMACEUTICALS, INC.

Trace Sioussat

Registration No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820